Home

EnGeneIC Announces Board Appointment - Professor Bryan Williams
READ MORE
WATCH
The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.
EnGeneIC treats Port Macquarie teen in world-first treament for rare cancer
READ MORE
We need healthy heroes to volunteer for EnGeneIC's therapeutic vaccine trial against COVID 19
Stay tuned for more information
previous arrowprevious arrow
next arrownext arrow
Shadow
Slider

 

 

 

 

 

 

 

Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology

Publication in prestigious scientific journal, Cancer Cell, highlighting the ability of EDV™ Nanocells to mount dual assault on Cancer Cells

EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival

Abstract accepted  to the Annual Meeting of the American Society of Clinical Oncology 2020

Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer.